Cyclic RGD-polyethylene Glycol-Polyethylenimine for Intracranial Glioblastoma-Targeted Gene Delivery.

Changyou Zhan,Qinggang Meng,Qinghua Li,Linglin Feng,Jianhua Zhu,Weiyue Lu

DOI: https://doi.org/10.1002/asia.201100570

2011-01-01

Chemistry - An Asian Journal

Abstract:Even though the bloodbrain barrier (BBB) is compromised for angiogenesis, therapeutic agents for glioblastoma multiforme (GBM) are particularly inefficient due to the existence of a bloodtumor barrier (BTB), which hampers tumor accumulation and uptake. Integrin av beta 3 is overexpressed on glioblastoma U87 cells and neovasculture, thus making its ligands such as the RGD motif target glioblastoma in vitro and in vivo. In the present work, we have designed a modified polyethylene glycolpolyethylenimine (PEGPEI) gene carrier by conjugating it with a cyclic RGD sequence, c(RGDyK) (cyclic arginine-glycine-aspartic acid-D-tyrosine-lysine). When complexed with plasmid DNA, this gene carrier, termed RGDPEGPEI, formed homogenous nanoparticles with a mean diameter of 73 nm. These nanoparticles had a high binding affinity with U87 cells and facilitated targeted gene delivery against intracranial glioblastoma in vivo, thereby leading to a higher gene transfer efficiency compared to the PEGPEI gene carrier without RGD decoration. This intracranial glioblastoma-targeted gene carrier also enhanced the therapeutic efficacy of pORF-hTRAIL, as evidenced by a significantly prolonged survival of intracranial glioblastoma-bearing nude mice. Considering the contribution of glioblastoma neovasculature to the BBB under angiogenic conditions, our results demonstrated the therapeutic feasibility of treating a brain tumor through mediation of integrin av beta 3, as well as the potential of using RGDPEGPEI as a targeted gene carrier in the treatment of intracranial glioblastoma.